Medicine
|
Oncology |
|
|
|
Home > Disciplines > Medicine > Oncology > Prostate cancer > Treatment > CSPC |
|
|
|
|
Metastatic and Non-metastatic castration-sensitive |
|
. |
Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, Gao AC, Yang Y, Shu
K, Liu J, Zhao P, Shen P, Zeng H. |
|
|
Metastatic castration-sensitive (mCSPC, M1) |
|
|
|
OVERVIEW |
|
. |
Hamilou Z, Baciarello G, Fizazi K. |
|
|
. |
Saad F. |
|
|
IDENTIFY MEN MORE LIKELY TO BENEFIT |
|
. |
Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard
S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M,
Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J,
DiPaola R, Sweeney C. |
|
|
PREDICTION OF TIME TO HORMONAL TREATMENT FAILURE |
|
. |
Jadvar H, Velez E, Desai B, Ji L, Colletti PM, Quinn DI.
|
|
|
ENZALUTAMIDE WITH STANDARD FIRST-LINE THERAPY |
|
|
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S,
Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM,
Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North
SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A,
Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang
AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the
Australian and New Zealand Urogenital and Prostate Cancer Trials
Group. |
|
|
Non-Metastatic castration-sensitive (non-mCSPC, M0) |
|
|
|
. |
Fang D, Zhou L. |
|
|
|
|
|
|